Dr. Philippe Armand, MD, PHD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 242
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of California, San Francisco School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MN license 82356 -
Hematology & Oncology Physician
MA license 219958
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Mayo Clinic Hospital Rochester Rochester, MN
- North Shore Medical Center - Salem, MA
Medical groups
- Mayo Clinic (4,956 clinicians)
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 242
- Services billed
- 434
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 133 | 112 |
| Established patient office or other outpatient visit, 30-39 minutes | 104 | 68 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 78 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 58 | 25 |
| Established patient office or other outpatient visit, 40-54 minutes | 49 | 39 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Hospital discharge day management, 30 minutes or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Rochester, MN | 41 |
| Brukinsa (zanubrutinib) | 38 |
| Jakafi (ruxolitinib phosphate) | 36 |
| Acyclovir Other prescribers in Rochester, MN | 26 |
| Prednisone Other prescribers in Rochester, MN | 24 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Rochester, MN | 18 |
| Rosuvastatin Calcium Other prescribers in Rochester, MN | 17 |
| Eliquis (apixaban) Other prescribers in Rochester, MN | 17 |
| Atorvastatin Calcium Other prescribers in Rochester, MN | 16 |
| Omeprazole Other prescribers in Rochester, MN | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 16 payments worth $27,881 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $14,313 |
|---|---|
| Pfizer Inc. | $5,340 |
| Merck Sharp & Dohme LLC | $5,185 |
| AbbVie Inc. | $1,800 |
| Eli Lilly and Company | $1,200 |
| AstraZeneca Pharmaceuticals LP | $43.25 |
| Consulting Fee | $27,592 |
|---|---|
| Food and Beverage | $160 |
| Travel and Lodging | $85.29 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 14, 2025 | Consulting Fee | $14,067 |
| Pfizer Inc. Sep 2, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $2,670 |
| Pfizer Inc. Sep 2, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $2,670 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $1,800 |
| Merck Sharp & Dohme LLC Jan 8, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,678 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $1,220 |
| Eli Lilly and Company Nov 12, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,200 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $915 |
| Merck Sharp & Dohme LLC Jun 11, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $915 |
| Merck Sharp & Dohme LLC May 12, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $458 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| Eli Lilly and Company Nov 12, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,200 |
| E.r. Squibb & Sons, L.l.c. Oct 14, 2025 | Consulting Fee | $14,067 |
| E.r. Squibb & Sons, L.l.c. Oct 14, 2025 | Travel and Lodging travel to BOSTON, MA | $85.29 |
| Pfizer Inc. Sep 2, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $2,670 |
| Pfizer Inc. Sep 2, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $2,670 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $915 |
| Merck Sharp & Dohme LLC Jun 11, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $915 |
| Merck Sharp & Dohme LLC May 12, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $458 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $1,220 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $1,800 |
| Merck Sharp & Dohme LLC Jan 8, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,678 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.